{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:51:32Z","timestamp":1790484692065,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The therapeutic potential of immune checkpoint inhibitors is currently being investigated in epithelial ovarian cancer (EOC), but immunological effects of the programmed cell death protein 1 (PD-1)\/programmed cell death 1 ligand 1 (PD-L1) axis in EOC still remain poorly understood. The aim of this study was thus to compare infiltration rates of PD-1 and PD-L1 expressing tumor infiltrating leucocytes (TILs) in primary ovarian tumor tissue and metastatic intraperitoneal implants and to investigate its impact on overall survival (OS). Tumor specimens (ovarian tumor tissues and intraperitoneal metastases) of 111 patients were used to investigate the PD-1, PD-L1 and CD8 expression rates on TILs and PD-L1 expression rate of tumor cells. The percentages of CD8, PD-1, and PD-L1 expressing subpopulations of TILs differ in primary ovarian tumor tissues and metastatic intraperitoneal implants. High PD-1 among TILs in peritoneal metastases were associated with favorable OS. High PD-L1 expression in TILs was associated with poor OS. Combining both factors in peritoneal metastases revealed an unfavorable prognosis. Primary ovarian tumor tissue and intraperitoneal metastatic tissues in EOC might have different strategies to evade immune control. Those findings are of importance for the process of biomarker assessment to predict patients\u2019 response to immunotherapy.<\/jats:p>","DOI":"10.1038\/s41598-021-85966-0","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:47:41Z","timestamp":1616086061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome"],"prefix":"10.1038","volume":"11","author":[{"given":"Christine","family":"Bekos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Dekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reinthaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Polterauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schwameis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Aust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"85966_CR1","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694 (2012).","journal-title":"N. Engl. J. Med."},{"key":"85966_CR2","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372, 2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596 (2015).","journal-title":"N. Engl. J. Med."},{"key":"85966_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257\u2013265. https:\/\/doi.org\/10.1016\/S1470-2045(15)70054-9 (2015).","journal-title":"Lancet Oncol."},{"key":"85966_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12030548","volume":"12","author":"S Aust","year":"2020","unstructured":"Aust, S. et al. Precision medicine tumor boards: clinical applicability of personalized treatment concepts in Ovarian cancer. Cancers (Basel) 12, 1. https:\/\/doi.org\/10.3390\/cancers12030548 (2020).","journal-title":"Cancers (Basel)"},{"key":"85966_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087. https:\/\/doi.org\/10.1093\/annonc\/mdz135 (2019).","journal-title":"Ann. Oncol."},{"key":"85966_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis, M. L. et al. Efficacy and safety of avelumab for patients with recurrent or refractory Ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol 5, 393\u2013401. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6258 (2019).","journal-title":"JAMA Oncol"},{"key":"85966_CR7","doi-asserted-by":"publisher","first-page":"17261","DOI":"10.18632\/oncotarget.3746","volume":"6","author":"K Auer","year":"2015","unstructured":"Auer, K. et al. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget 6, 17261\u201317275. https:\/\/doi.org\/10.18632\/oncotarget.3746 (2015).","journal-title":"Oncotarget"},{"key":"85966_CR8","doi-asserted-by":"publisher","first-page":"61336","DOI":"10.18632\/oncotarget.11038","volume":"7","author":"K Auer","year":"2016","unstructured":"Auer, K. et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget 7, 61336\u201361354. https:\/\/doi.org\/10.18632\/oncotarget.11038 (2016).","journal-title":"Oncotarget"},{"key":"85966_CR9","doi-asserted-by":"publisher","first-page":"42929","DOI":"10.1038\/srep42929","volume":"7","author":"S Aust","year":"2017","unstructured":"Aust, S. et al. Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer. Sci. Rep. 7, 42929. https:\/\/doi.org\/10.1038\/srep42929 (2017).","journal-title":"Sci. Rep."},{"key":"85966_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat. Immunol. 21, 442\u2013454. https:\/\/doi.org\/10.1038\/s41590-020-0620-x (2020).","journal-title":"Nat. Immunol."},{"key":"85966_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537\u20131544. https:\/\/doi.org\/10.1182\/blood-2008-12-195792 (2009).","journal-title":"Blood"},{"key":"85966_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-2407-13-115","volume":"13","author":"S Aust","year":"2013","unstructured":"Aust, S. et al. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC Cancer 13, 115. https:\/\/doi.org\/10.1186\/1471-2407-13-115 (2013).","journal-title":"BMC Cancer"},{"key":"85966_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11091250","volume":"11","author":"K Dotzer","year":"2019","unstructured":"Dotzer, K. et al. Immune heterogeneity between primary tumors and corresponding metastatic lesions and response to platinum therapy in primary ovarian cancer. Cancers (Basel) 11, 1. https:\/\/doi.org\/10.3390\/cancers11091250 (2019).","journal-title":"Cancers (Basel)"},{"key":"85966_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/1471-2407-13-422","volume":"13","author":"A Bachmayr-Heyda","year":"2013","unstructured":"Bachmayr-Heyda, A. et al. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients\u2013a study of the OVCAD consortium. BMC Cancer 13, 422. https:\/\/doi.org\/10.1186\/1471-2407-13-422 (2013).","journal-title":"BMC Cancer"},{"key":"85966_CR15","doi-asserted-by":"publisher","first-page":"15621","DOI":"10.18632\/oncotarget.14919","volume":"8","author":"J Li","year":"2017","unstructured":"Li, J., Wang, J., Chen, R., Bai, Y. & Lu, X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget 8, 15621\u201315631. https:\/\/doi.org\/10.18632\/oncotarget.14919 (2017).","journal-title":"Oncotarget"},{"key":"85966_CR16","doi-asserted-by":"publisher","unstructured":"Ovarian Tumor Tissue Analysis, C. et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 3, e173290. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290 (2017).","DOI":"10.1001\/jamaoncol.2017.3290"},{"key":"85966_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1039\/c8mo00128f","volume":"14","author":"L Yang","year":"2018","unstructured":"Yang, L. et al. Clinical significance of the immune microenvironment in ovarian cancer patients. Mol. Omics 14, 341\u2013351. https:\/\/doi.org\/10.1039\/c8mo00128f (2018).","journal-title":"Mol. Omics"},{"key":"85966_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13048-019-0526-0","volume":"12","author":"KH Kim","year":"2019","unstructured":"Kim, K. H. et al. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. J. Ovar. Res. 12, 56. https:\/\/doi.org\/10.1186\/s13048-019-0526-0 (2019).","journal-title":"J. Ovar. Res."},{"key":"85966_CR19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053\u20131064. https:\/\/doi.org\/10.2353\/ajpath.2010.100105 (2010).","journal-title":"Am. J. Pathol."},{"key":"85966_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248\u20131259. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1248 (2002).","journal-title":"J. Clin. Oncol."},{"key":"85966_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/PGP.0b013e31820d20ba","volume":"30","author":"M Kobel","year":"2011","unstructured":"Kobel, M. et al. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int. J. Gynecol. Pathol. 30, 366\u2013371. https:\/\/doi.org\/10.1097\/PGP.0b013e31820d20ba (2011).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"85966_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/path.4230","volume":"231","author":"A Bashashati","year":"2013","unstructured":"Bashashati, A. et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231, 21\u201334. https:\/\/doi.org\/10.1002\/path.4230 (2013).","journal-title":"J. Pathol."},{"key":"85966_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1186\/s12885-015-1952-z","volume":"15","author":"A Mota","year":"2015","unstructured":"Mota, A. et al. Intra-tumor heterogeneity in TP53 null high grade serous ovarian carcinoma progression. BMC Cancer 15, 940. https:\/\/doi.org\/10.1186\/s12885-015-1952-z (2015).","journal-title":"BMC Cancer"},{"key":"85966_CR24","doi-asserted-by":"publisher","first-page":"e77825","DOI":"10.1371\/journal.pone.0077825","volume":"8","author":"G Mittermeyer","year":"2013","unstructured":"Mittermeyer, G. et al. Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer. PLoS ONE 8, e77825. https:\/\/doi.org\/10.1371\/journal.pone.0077825 (2013).","journal-title":"PLoS ONE"},{"key":"85966_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez, A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927\u2013938. https:\/\/doi.org\/10.1016\/j.cell.2017.07.025 (2017).","journal-title":"Cell"},{"key":"85966_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547\u2013562. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.012 (2018).","journal-title":"Cancer Cell"},{"key":"85966_CR27","doi-asserted-by":"publisher","first-page":"102602","DOI":"10.1016\/j.ebiom.2019.102602","volume":"51","author":"R Liu","year":"2020","unstructured":"Liu, R., Hu, R., Zeng, Y., Zhang, W. & Zhou, H. H. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: a gene expression-based computational study. EBioMedicine 51, 102602. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102602 (2020).","journal-title":"EBioMedicine"},{"key":"85966_CR28","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.18632\/oncotarget.6429","volume":"7","author":"S Darb-Esfahani","year":"2016","unstructured":"Darb-Esfahani, S. et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 7, 1486\u20131499. https:\/\/doi.org\/10.18632\/oncotarget.6429 (2016).","journal-title":"Oncotarget"},{"key":"85966_CR29","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-14-0239","volume":"3","author":"JR Webb","year":"2015","unstructured":"Webb, J. R., Milne, K. & Nelson, B. H. PD-1 and CD103 Are Widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. Cancer Immunol. Res. 3, 926\u2013935. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0239 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"85966_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00428-020-02751-6","volume":"477","author":"L Martin de la Fuente","year":"2020","unstructured":"Martin de la Fuente, L. et al. PD-1\/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. Virchows Arch. 477, 83\u201391. https:\/\/doi.org\/10.1007\/s00428-020-02751-6 (2020).","journal-title":"Virchows Arch."},{"key":"85966_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb, J. R., Milne, K., Kroeger, D. R. & Nelson, B. H. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141, 293\u2013302. https:\/\/doi.org\/10.1016\/j.ygyno.2016.03.008 (2016).","journal-title":"Gynecol Oncol"},{"key":"85966_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren, S. & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by Chained Equations in R. J. Stat. Softw. 45, 67. https:\/\/doi.org\/10.18637\/jss.v045.i03 (2011).","journal-title":"J. Stat. Softw."},{"key":"85966_CR33","volume-title":"Modern Applied Statistics with S","author":"WN Venables","year":"2003","unstructured":"Venables, W. N. & Ripley, B. D. Modern Applied Statistics with S (Springer, 2003)."},{"key":"85966_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","volume":"30","author":"C Contal","year":"1999","unstructured":"Contal, C. & O\u2019Quigley, J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput. Stat. Data Anal. 30, 253\u2013270. https:\/\/doi.org\/10.1016\/S0167-9473(98)00096-6 (1999).","journal-title":"Comput. Stat. Data Anal."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85966-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85966-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85966-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:44:09Z","timestamp":1670046249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85966-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85966"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85966-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"23 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6400"}}